表紙
市場調查報告書

糖尿病管理:血糖儀的全球市場

Diabetes Management: Blood Glucose Monitoring Devices Market

出版商 Datamonitor Healthcare 商品編碼 858203
出版日期 內容資訊 英文 141 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
糖尿病管理:血糖儀的全球市場 Diabetes Management: Blood Glucose Monitoring Devices Market
出版日期: 2019年12月19日內容資訊: 英文 141 Pages
簡介

現在,全球整體約有4億2500萬人成人 (20∼79歲)的糖尿病患者存在,而預計2045年其數對增加到6億2900萬人。血糖儀成為糖尿病患者的健康管理不可或缺的裝置。全球血糖儀 (BGMD)的市場規模,2018年約80億美元,2023年將達130億美元,預計以約11%的年複合成長率 (CAGR) 擴大。對高性能產品的需求和技術不斷進步,市場規模 (治療費)的順利擴大預測等,預計成為今後市場的促進因素。另一方面,價格競爭加劇和市場飽和化,廉價的檢驗紙的競爭等要素,也有降低市場成長率的可能性。

本報告提供全球血糖儀市場相關分析,疾病概要,及主要已上市/開發中產品,主要的推動及阻礙市場要素和今後的市場機會,市場規模的預測 (今後5年份),市場佔有率結構,主要企業的簡介和財務分析、成長策略等資訊彙整,為您概述為以下內容。

摘要整理

第2章 疾病概要

  • 患者數
  • 糖尿病定義
    • 症狀
    • 並存症
    • 診斷、治療方法
    • 糖尿病的成本
  • 參考文獻

第2章 血糖儀

  • 血糖儀
    • Abbott
    • Ascensia Diabetes Care
    • LifeScan/Platinum Equity
    • Roche
    • Livongo
    • One Drop/Apple Watch
  • 持續血糖儀 (CBM)
    • Abbott
    • Dexcom
    • Medtronic
  • 新型的穿戴式血糖監測系統
    • Medtronic: glucose-sensing patch
    • Nemaura Medical
    • Senseonics
    • Verily
  • 糖尿病監測用行動應用程式
  • 參考文獻

第3章 市場分析

  • 血糖儀市場
    • 市場預測:全球
    • 市場預測:各地區、各領域
    • 美國市場
    • (EU5) 市場歐洲主要5個國家
    • 日本市場
    • 其他的國家 (RoW)的市場
    • 推動及阻礙市場要素
  • 競爭分析
    • 市場佔有率:全球整體/綜合分析
    • 市場佔有率:各領域
    • 市場佔有率:各地區
  • 企業簡介
    • Abbott
    • Ascensia Diabetes Care
    • Dexcom
    • Medtronic
    • Nemaura Medical
    • Roche
    • Senseonics
  • 參考文獻

附錄:企業一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: #MDT19020

Overview:

According to the International Diabetes Federation (IDF), approximately 425 million adults (20-79 years of age) have diabetes worldwide, and this number is expected to rise nearly 50% to approximately 629 million by 2045. More than 1.25 million people have type 1 diabetes in the US alone.

Blood glucose monitoring is essential for people with diabetes to lower the risk of complications. It is particularly important for those with type 1 diabetes, but also in people with type 2 diabetes who frequently administer insulin and/or suffer from symptomatic blood sugar fluctuations.

Blood glucose monitoring devices include both traditional handheld blood glucose meters (BGMs) used by patients at home and by healthcare practitioners at the point-of-care, and new sophisticated continuous glucose monitoring systems (CGMs) used by type 1 and insulin-dependent type 2 diabetics.

Valued at nearly $8bn in 2018, the global Blood Glucose Monitoring Devices (BGMDs) Market is growing at a fast pace-at a compound annual growth rate (CAGR) of approximately 11%-due to the phenomenal sales growth of new revolutionary CGMs, such as Abbott's FreeStyle Libre and Dexcom's G6 CGM. The market is expected to total nearly $13bn by 2023­. Growth of CGMs will be offset by a steady decline in the BGMs segment due to continued extreme price competition/downward pricing pressure, lowered test-strip reimbursement, and market saturation of lower-cost meters, among other factors.

The overall BGMDs market is being driven by several positive factors, including:

  • strong demand for discreet, accurate CGM devices that provide convenient blood glucose monitoring 24/7 and eliminate frequent/cumbersome and painful fingersticks
  • steadily increasing awareness and adoption of new, next-generation CGMs (by Abbott and Dexcom) driven by strong sales/marketing/advertising and physician referrals
  • solid clinical outcomes due to the ability to improve the accuracy of insulin delivery and improve glycemic control or time-in-range (TIR) via continuous (24/7) glucose monitoring
  • the ability to integrate lucrative CGM sensors into fast-growing next-generation hybrid closed-loop insulin pump systems (eg MiniMed 670G, Tandem's t:slim, and future pump systems; see below Insulin Pumps report)
  • better patient awareness and physician understanding of glucose trends and impact of diet/medication/exercise/lifestyle factors due to the use of smartphone-driven digital health coaching apps, resulting in improved diabetes management
  • ability to lower overall healthcare costs
  • solid reimbursement
  • low CGM market penetration (due to newness of technology), leaving much room for market growth in a large and expanding diabetes population
  • sales of lucrative recurring CGM disposables (eg sensors) and accessories.

This comprehensive medical market and technology report provides:

  • prevalence of diabetes
  • BGM/CGM product portfolios and technical innovations
  • product pipelines/emerging technologies/startups
  • trends and opportunities
  • market drivers and limiters
  • market and competitive analysis-including 5-year global and regional market forecasts, global/regional market share (2018), company overview, financials, and strategic growth plans.

Markets covered by this analysis include the US, Japan, the five major EU markets (France, Germany, Italy, Spain, and the UK), and the Rest of World (RoW) markets, which includes all other countries. Market forecasts are for the 2018-23 time period.

Table of Contents

Executive Summary

  • i. Diabetes overview
  • ii. Blood glucose monitoring technology
  • iii. Global blood glucose monitoring devices market
  • iv. Competition
  • v. Methodology
  • vi. Bibliography
  • Exhibit ES-1: Blood glucose monitoring device sales by product segment, combined market forecast ($m), 2018-23

1. Diabetes Overview

  • 1.1. Prevalence
  • 1.2. Diabetes defined
    • 1.2.1. Symptoms
    • 1.2.2. Complications
    • 1.2.3. Diagnosis and treatment
    • 1.2.4. Cost of diabetes
  • 1.3. Bibliography

2. Blood Glucose Monitoring Devices

  • 2.1. Blood glucose meters
    • 2.1.1. Abbott
    • 2.1.2. Ascensia Diabetes Care
    • 2.1.3. LifeScan/Platinum Equity
    • 2.1.4. Roche
    • 2.1.5. Livongo
    • 2.1.6. One Drop/Apple Watch
  • 2.2. Continuous blood glucose monitoring systems
    • 2.2.1. Abbott
    • 2.2.2. Dexcom
    • 2.2.3. Medtronic
  • 2.3. New or emerging wearable blood glucose monitoring patches
    • 2.3.1. Medtronic: glucose-sensing patch
    • 2.3.2. Nemaura Medical
    • 2.3.3. Senseonics
    • 2.3.4. Verily
  • 2.4. Diabetes monitoring mobile apps
  • 2.5. Bibliography
  • Exhibit 2-1: Accuracy of blood glucose meters - top 8 with lowest MARD
  • Exhibit 2-2: Selected blood glucose meter brands by manufacturer
  • Exhibit 2-3: Selected blood glucose meters and features
  • Exhibit 2-4: The FreeStyle Lite
  • Exhibit 2-5: The Contour NEXT One and Contour Diabetes app
  • Exhibit 2-6: The Contour NEXT Link 2.4
  • Exhibit 2-7: OneTouch Verio Flex meter with OneTouch Reveal app and OneTouch Verio meter
  • Exhibit 2-8: OneTouch Reveal Plus powered by Welldoc's BlueStar intelligent diabetes coaching technology
  • Exhibit 2-9: Welldoc's BlueStar diabetes AI-driven smart app
  • Exhibit 2-10: The new Accu-Chek Guide, Guide me, and mySugr app
  • Exhibit 2-11: One Drop Mobile app, glucose meter/accessories, and the Apple Watch
  • Exhibit 2-12: Selected continuous glucose monitoring systems by manufacturer
  • Exhibit 2-13: Selected continuous glucose monitoring systems and features
  • Exhibit 2-14: The FreeStyle Libre 14-day CGM System
  • Exhibit 2-15: The LibreLink app
  • Exhibit 2-16: The Dexcom G6 CGM System with extended 10-day sensor
  • Exhibit 2-17: Dexcom CLARITY diabetes management software
  • Exhibit 2-18: The Guardian Connect CGM System with Sugar.IQ app
  • Exhibit 2-19: The iPro2 Professional CGM system with CareLink iPro software
  • Exhibit 2-20: The SugarBEAT system
  • Exhibit 2-21: How the SugarBEAT draws glucose from interstitial fluid
  • Exhibit 2-22: Senseonic's Eversense Continuous Glucose Monitoring System and insertion procedure
  • Exhibit 2-23: Verily Lifesciences' investigational glucose-measuring contact lens

3. Market Analysis

  • 3.1. Blood glucose monitoring devices market
    • 3.1.1. Market forecast: global
    • 3.1.2. Market forecast: by region and segment
    • 3.1.3. US market
    • 3.1.4. Five major EU markets
    • 3.1.5. Japanese market
    • 3.1.6. Rest of the world market
    • 3.1.7. Market drivers and limiters
  • 3.2. Competitive analysis
    • 3.2.1. Market share: global/combined
    • 3.2.2. Market share: by segment
    • 3.2.3. Market share: by region
  • 3.3. Corporate profiles
    • 3.3.1. Abbott
    • 3.3.2. Ascensia Diabetes Care
    • 3.3.3. Dexcom
    • 3.3.4. Medtronic
    • 3.3.5. Nemaura Medical
    • 3.3.6. Roche
    • 3.3.7. Senseonics
  • 3.4. Bibliography
  • Exhibit 3-1: Blood glucose monitoring device sales by product segment, combined market forecast ($m), 2018-23
  • Exhibit 3-2: Blood glucose monitoring devices market, forecast sales by region ($m), 2018-23
  • Exhibit 3-3: Blood glucose monitoring device sales by product segment and region, combined market forecast ($m), 2018-23
  • Exhibit 3-4: Combined blood glucose monitoring devices market, global share by supplier ($m), 2018
  • Exhibit 3-5: Blood glucose meters market, global share by supplier ($m), 2018
  • Exhibit 3-6: Continuous glucose monitoring systems market, global share by supplier ($m), 2018
  • Exhibit 3-7: Combined blood glucose monitoring devices market, estimated share by supplier and region, 2018
  • Exhibit 3-8: Abbott, revenues by segment, FY2018
  • Exhibit 3-9: Dexcom, revenues by segment, FY2018
  • Exhibit 3-10: Medtronic, revenues by segment, FY2019
  • Exhibit 3-11: Roche, revenues by segment, FY2018
  • Exhibit 3-12: Senseonics, revenues by segment, FY2018

Appendix A: company listing

Back to Top